Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) closed at $82.17 down -9.90% from its previous closing price of $91.20. In other words, the price has decreased by -$9.90 from its previous closing price. On the day, 7.88 million shares were traded. BMRN stock price reached its highest trading level at $86.78 during the session, while it also had its lowest trading level at $81.0.
Ratios:
For a deeper understanding of Biomarin Pharmaceutical Inc.’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 14.90 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 85.77. For the most recent quarter (mrq), Quick Ratio is recorded 1.70 and its Current Ratio is at 2.74. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on November 15, 2023, initiated with a Overweight rating and assigned the stock a target price of $100.
On October 23, 2023, Bernstein Upgraded its rating to Mkt Perform which previously was Underperform but kept the price unchanged to $82.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 12 ’24 when BIENAIME JEAN JACQUES sold 20,000 shares for $91.26 per share. The transaction valued at 1,825,200 led to the insider holds 474,994 shares of the business.
BIENAIME JEAN JACQUES sold 20,000 shares of BMRN for $1,819,800 on Apr 11 ’24. The Director now owns 474,994 shares after completing the transaction at $90.99 per share. On Apr 10 ’24, another insider, Burkhart Erin, who serves as the GVP, Chief Accounting Officer of the company, sold 2,286 shares for $90.00 each. As a result, the insider received 205,740 and left with 16,156 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMRN now has a Market Capitalization of 15593811968 and an Enterprise Value of 15635322880. As of this moment, Biomarin’s Price-to-Earnings (P/E) ratio for their current fiscal year is 76.82, and their Forward P/E ratio for the next fiscal year is 32.68. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.79. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.30 while its Price-to-Book (P/B) ratio in mrq is 3.07. Its current Enterprise Value per Revenue stands at 6.326 whereas that against EBITDA is 53.277.
Stock Price History:
Over the past 52 weeks, BMRN has reached a high of $99.56, while it has fallen to a 52-week low of $76.02. The 50-Day Moving Average of the stock is -6.39%, while the 200-Day Moving Average is calculated to be -7.77%.
Shares Statistics:
For the past three months, BMRN has traded an average of 1.41M shares per day and 2164420 over the past ten days. A total of 188.60M shares are outstanding, with a floating share count of 185.93M. Insiders hold about 2.03% of the company’s shares, while institutions hold 98.79% stake in the company. Shares short for BMRN as of 1713139200 were 3688638 with a Short Ratio of 2.62, compared to 1710460800 on 2964290. Therefore, it implies a Short% of Shares Outstanding of 3688638 and a Short% of Float of 1.96.
